Tiziana Life Sciences is trading 6.25% higher at $0.71 after reporting positive topline results from its Phase 2a INFORM-MS trial of nasal foralumab. - The trial met its primary endpoints, including reduced microglial activation at the 50 μg dose and safety; fatigue scores also improved. - At the 100 μg dose, the imaging measure did not improve significantly, and disability scores were unchanged during the 12-week study. - Results were early-stage and mixed across doses; shares had fallen 16.25% on November 2 before this move.